Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-07
2008-08-26
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S121000
Reexamination Certificate
active
07417053
ABSTRACT:
A pyrazolo[1,5-a]pyridine derivative represented by formula (I) and salt thereof exhibit excellent MAPKAP-K2 inhibitory activity. Accordingly, medicines comprising this compound as an active ingredient are expected to be valuable for treating or preventing diseases mediated by MAPKAP-K2 such as inflammatory injury, autoimmune diseases, asteropathia destruens, cancer and/or growth of tumor.
REFERENCES:
patent: 2001/139575 (2001-05-01), None
patent: 2001139575 (2001-05-01), None
patent: WO 2004/026872 (2004-04-01), None
patent: WO 2004/026872 (2004-04-01), None
patent: WO 2004/054504 (2004-07-01), None
patent: WO 2004/054505 (2004-07-01), None
patent: WO 2004/055015 (2004-07-01), None
patent: WO 2004/055019 (2004-07-01), None
patent: WO 2004/058176 (2004-07-01), None
patent: WO 2004/058762 (2004-07-01), None
patent: WO 2004/076458 (2004-09-01), None
patent: WO 2004/081013 (2004-09-01), None
patent: WO 2004/099127 (2004-11-01), None
patent: WO 2005/007092 (2005-01-01), None
patent: WO 2005/009370 (2005-02-01), None
patent: WO 2005/028445 (2005-03-01), None
patent: WO 2005/077948 (2005-08-01), None
Enrique Martin-Blanco, “p38 MAPK signalling cascades: ancient roles and new functions”, BioEssays 22.7, pp. 637-645, 2000 John Wiley & Sons, Inc.
H. Y. Shin et al., “Regulatory Effect of Cytokine Production in Patients With Cerebral Infarction by Yulda-Hanso-Tang”, Immunopharmacology and Immunotoxicology, 22(2), pp. 183-193, (2000).
David Stokoe et al., “Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins”, Federation of European Biochemical Societies, vol. 313, No. 3, pp. 307-313, published by Elsevier Science Publications, Nov. 1992.
Oliver Werz et al, “5-Lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases”, PNAS, May 9, 2000, vol. 97, No. 10, pp. 5261-5266.
Olaf Heidenreich et al., “MAPKAP Kinase 2 Phosphorylates Serum Response Factor in Vitro and in Vivo”, The Journal of Biological Chemistry, vol. 274, No. 20, Issue of May 14, pp. 14434-14443, published by The American Society for Biochemistry and Molecular Biology, Inc., 1999.
Yi Tan et al., “FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2”, The EMBO Journal, vol. 15, No. 17, pp. 4629-4642, published by Oxford University Press, 1996.
Bernd Neufeld et al, “Serine/Threonine Kinases 3pK and MAPK-activated Protein Kinase 2 Interact with the Basic Helix-Loop-Helix Transcription Factor E47 and Repress Its Transcriptional Activity”, The Journal of Biological Chemistry, vol. 275, No. 27, Jul. 7, 2000 pp. 20239-20242, published by The American Society for Biochemistry and Molecular Biology, Inc., 2000.
Davis Stokoe, et al., “The substrate specificity and structure of mitrogen-activated protein (MAP) kinase-activated protein kinase-2”, Biochem J. (1993) 296, pp. 843-849.
Alexey Kotlyarov et al., MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis, Macmillian Magazines LtdNature Cell Biology, vol. 1, Jun. 1999.
Xinkang Wang et al., “Mitogen-activated Protein Kinase-activated Protei (MAPKAP) Kinase 2 Deficiency Protects Brain from Ischemic Injury in Mice”, The Journal of Biological Chemistry, vol. 277, No. 46, Issues of Nov. 15, pp. 43968-43972, 2002 published by the American Society for Biochemistry and Molecular Biology, Inc.
Isaac A. Manke et al., “MAPKAP Kinase-2 Is a Cell Cycle Checkpoint Kinase that Regulates the G2/M Transition and S Phase Progression in Response to UV Irradiation”, Molecular Cell, vol. 17, pp. 37-48, Jan. 7, 2005 published by Elsevier Inc. 2005.
Hamada Motoko
Kataoka Ken-ichiro
Kosugi Tomomi
Makino Hiroaki
Matsueda Yohei
Rahmani Niloofar
Seaman D. Margaret
Sughrue & Mion, PLLC
Teijin Pharma Limited
LandOfFree
Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002530